Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
SUMMARY
According to the recently published report 'Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update'; Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) pipeline Target constitutes close to 37 molecules.
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Non-receptor tyrosine-protein kinase TYK2 is an enzyme encoded by the TYK2 gene. It is involved in intracellular signal transduction by involving in the initiation of type I IFN signaling. It phosphorylates the interferon-alpha/beta receptor alpha chain. It plays an import role in inflammation.
The report outlays comprehensive information on the Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 6, 9, 2, 12 and 6 respectively. Report covers products from therapy areas Immunology, Gastrointestinal, Dermatology, Musculoskeletal Disorders, Oncology, Central Nervous System, Infectious Disease, Respiratory, Metabolic Disorders, Ophthalmology and Undisclosed which include indications Autoimmune Disorders, Psoriasis, Systemic Lupus Erythematosus, Plaque Psoriasis (Psoriasis Vulgaris), Inflammatory Bowel Disease, Rheumatoid Arthritis, Atopic Dermatitis (Atopic Eczema), Psoriatic Arthritis, Ulcerative Colitis, Inflammation, Unspecified Immunological Disorders, Asthma, Colorectal Cancer, Coronavirus Disease 2019 (COVID-19), Crohn's Disease (Regional Enteritis), Dermatomyositis, Multiple Sclerosis, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), Alopecia Areata, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Cutaneous Lupus Erythematosus (CCLE)/Discoid Lupus Erythematosus (DLE), Chronic Obstructive Pulmonary Disease (COPD), Chronic Urticaria Or Hives, Colon Cancer, Cutaneous T-Cell Lymphoma, Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, Enteritis, Fibrosis, Follicular Lymphoma, Hidradenitis Suppurativa, Intermediate Uveitis, Kidney Cancer (Renal Cell Cancer), Lupus Erythematosus, Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Neuroinflammation, Non-infectious Uveitis, Pancreatic Cancer, Panuveitis, Peripheral T-Cell Lymphomas (PTCL), Posterior Uveitis, Skin Cancer, Solid Tumor, Subacute Cutaneous Lupus Erythematosus (SCLE), Unspecified, Unspecified B-Cell Lymphomas, Unspecified Dermatological Disorders, Vitiligo and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update'; Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) pipeline Target constitutes close to 37 molecules.
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Non-receptor tyrosine-protein kinase TYK2 is an enzyme encoded by the TYK2 gene. It is involved in intracellular signal transduction by involving in the initiation of type I IFN signaling. It phosphorylates the interferon-alpha/beta receptor alpha chain. It plays an import role in inflammation.
The report outlays comprehensive information on the Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 6, 9, 2, 12 and 6 respectively. Report covers products from therapy areas Immunology, Gastrointestinal, Dermatology, Musculoskeletal Disorders, Oncology, Central Nervous System, Infectious Disease, Respiratory, Metabolic Disorders, Ophthalmology and Undisclosed which include indications Autoimmune Disorders, Psoriasis, Systemic Lupus Erythematosus, Plaque Psoriasis (Psoriasis Vulgaris), Inflammatory Bowel Disease, Rheumatoid Arthritis, Atopic Dermatitis (Atopic Eczema), Psoriatic Arthritis, Ulcerative Colitis, Inflammation, Unspecified Immunological Disorders, Asthma, Colorectal Cancer, Coronavirus Disease 2019 (COVID-19), Crohn's Disease (Regional Enteritis), Dermatomyositis, Multiple Sclerosis, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), Alopecia Areata, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Cutaneous Lupus Erythematosus (CCLE)/Discoid Lupus Erythematosus (DLE), Chronic Obstructive Pulmonary Disease (COPD), Chronic Urticaria Or Hives, Colon Cancer, Cutaneous T-Cell Lymphoma, Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, Enteritis, Fibrosis, Follicular Lymphoma, Hidradenitis Suppurativa, Intermediate Uveitis, Kidney Cancer (Renal Cell Cancer), Lupus Erythematosus, Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Neuroinflammation, Non-infectious Uveitis, Pancreatic Cancer, Panuveitis, Peripheral T-Cell Lymphomas (PTCL), Posterior Uveitis, Skin Cancer, Solid Tumor, Subacute Cutaneous Lupus Erythematosus (SCLE), Unspecified, Unspecified B-Cell Lymphomas, Unspecified Dermatological Disorders, Vitiligo and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)
- The report reviews Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Overview
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
A2A Pharmaceuticals Inc
Alexion Pharmaceuticals Inc
Alumis Inc
Amgen Inc
Atomwise Inc
BeiGene Ltd
Bristol-Myers Squibb Co
Galapagos NV
Haisco Pharmaceutical Group Co Ltd
InnoCare Pharma Ltd
Kinaset Therapeutics Inc
Merck & Co Inc
Neuron23 Inc
Nimbus Therapeutics LLC
Oncostellae SL
Pfizer Inc
Priovant Therapeutics Inc
Sareum Holdings Plc
Shenzhen Chipscreen Biosciences Co Ltd
Simcere Pharmaceutical Group Ltd
Sudo Biosciences Inc
Technoderma Medicines Inc
Theravance Biopharma Inc
TLL Pharmaceutical LLC
Ventyx Biosciences Inc
Xilingyuan Pharmaceutical Co Ltd
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Drug Profiles
A2A-I-01 - Drug Profile
Product Description
Mechanism Of Action
BGB-23339 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BMS-986322 - Drug Profile
Product Description
Mechanism Of Action
History of Events
brepocitinib tosylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
cerdulatinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
CS-43001 - Drug Profile
Product Description
Mechanism Of Action
deucravacitinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
ESK-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
FTP-637 - Drug Profile
Product Description
Mechanism Of Action
History of Events
GLPG-3667 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ICP-332 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ICP-488 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KN-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NDI-031407 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NDI-034858 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Oral TYK2 (JH2) - Drug Profile
Product Description
Mechanism Of Action
OST-122 - Drug Profile
Product Description
Mechanism Of Action
History of Events
QY-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SAR-20347 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SDC-1801 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SDC-1802 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit JAK1 and TYK2 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit JAK1, JAK2 and TYK2 for Diabetic Macular Edema - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Asthma - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit TYK2 for Inflammatory Disorders and Neuroinflammation - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit TYK2 for Unspecified Immunological Disorders - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit JAK1, JAK2, JAK3 and TYK2 for Dermatology - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit TYK2 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
History of Events
SMP-117 - Drug Profile
Product Description
Mechanism Of Action
TDM-180935 - Drug Profile
Product Description
Mechanism Of Action
TDMSLE-01 - Drug Profile
Product Description
Mechanism Of Action
TLL-018 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TYK2 (JH2) Program 2 - Drug Profile
Product Description
Mechanism Of Action
TYK2 (JH2) Program 3 - Drug Profile
Product Description
Mechanism Of Action
TYK2 (JH2) Program 4 - Drug Profile
Product Description
Mechanism Of Action
VTX-958 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Dormant Products
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Discontinued Products
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Nov 08, 2022: Sareum Holdings : Update on SDC-1801 CTA application
Sep 28, 2022: Alumis announces initiation of patient dosing in phase 2 clinical trial of ESK-001 for the treatment of plaque psoriasis
Sep 12, 2022: Bristol Myers Squibb announces new Sotyktu (deucravacitinib) long-term data showing clinical efficacy maintained for up to two years with continuous treatment in moderate-to-severe plaque psoriasis
Sep 09, 2022: US FDA grants approval for BMS’ Sotyktu to treat plaque psoriasis
Aug 24, 2022: Nimbus Therapeutics presents new data on oral allosteric TYK2 inhibitor at American Chemical Society Meeting
Aug 15, 2022: Ventyx Biosciences announces positive topline phase 1 data for its selective allosteric TYK2 inhibitor VTX95
Aug 11, 2022: Ventyx Biosciences to report topline results from the phase 1 trial of its TYK 2 inhibitor VTX958 and second quarter 2022 financial results on August 15, 2022
Aug 02, 2022: InnoCare announces first subject dosed in clinical trial of TYK2 JH2 allosteric inhibitor ICP-488 in China
Jul 28, 2022: Sareum submits clinical trial authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an operational update
Jun 28, 2022: Roivant and Pfizer unveil Priovant Therapeutics and ongoing registrational studies for oral Brepocitinib in dermatomyositis and lupus
Jun 01, 2022: Late-Breaking data at EULAR 2022 demonstrate deucravacitinib significantly improved disease activity in phase 2 PAISLEY study in Systemic Lupus Erythematosus
Jun 01, 2022: Lupus Research Alliance and Lupus Therapeutics response to positive data from phase 2 study on potential first-in-class lupus treatment
May 19, 2022: Nimbus Therapeutics presents additional clinical data from phase 1 studies of oral allosteric TYK2 inhibitor at SID Annual Meeting
May 12, 2022: New two-year deucravacitinib data reinforce durable efficacy and consistent safety profile in treatment of moderate to severe plaque psoriasis
Apr 11, 2022: European patent granted for Sareum's SDC-1802, a novel small molecule TYK2/JAK1 inhibitor, for the treatment of T-cell acute lymphoblastic leukaemia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Overview
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
A2A Pharmaceuticals Inc
Alexion Pharmaceuticals Inc
Alumis Inc
Amgen Inc
Atomwise Inc
BeiGene Ltd
Bristol-Myers Squibb Co
Galapagos NV
Haisco Pharmaceutical Group Co Ltd
InnoCare Pharma Ltd
Kinaset Therapeutics Inc
Merck & Co Inc
Neuron23 Inc
Nimbus Therapeutics LLC
Oncostellae SL
Pfizer Inc
Priovant Therapeutics Inc
Sareum Holdings Plc
Shenzhen Chipscreen Biosciences Co Ltd
Simcere Pharmaceutical Group Ltd
Sudo Biosciences Inc
Technoderma Medicines Inc
Theravance Biopharma Inc
TLL Pharmaceutical LLC
Ventyx Biosciences Inc
Xilingyuan Pharmaceutical Co Ltd
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Drug Profiles
A2A-I-01 - Drug Profile
Product Description
Mechanism Of Action
BGB-23339 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BMS-986322 - Drug Profile
Product Description
Mechanism Of Action
History of Events
brepocitinib tosylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
cerdulatinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
CS-43001 - Drug Profile
Product Description
Mechanism Of Action
deucravacitinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
ESK-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
FTP-637 - Drug Profile
Product Description
Mechanism Of Action
History of Events
GLPG-3667 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ICP-332 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ICP-488 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KN-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NDI-031407 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NDI-034858 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Oral TYK2 (JH2) - Drug Profile
Product Description
Mechanism Of Action
OST-122 - Drug Profile
Product Description
Mechanism Of Action
History of Events
QY-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SAR-20347 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SDC-1801 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SDC-1802 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit JAK1 and TYK2 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit JAK1, JAK2 and TYK2 for Diabetic Macular Edema - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Asthma - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit TYK2 for Inflammatory Disorders and Neuroinflammation - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit TYK2 for Unspecified Immunological Disorders - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit JAK1, JAK2, JAK3 and TYK2 for Dermatology - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit TYK2 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
History of Events
SMP-117 - Drug Profile
Product Description
Mechanism Of Action
TDM-180935 - Drug Profile
Product Description
Mechanism Of Action
TDMSLE-01 - Drug Profile
Product Description
Mechanism Of Action
TLL-018 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TYK2 (JH2) Program 2 - Drug Profile
Product Description
Mechanism Of Action
TYK2 (JH2) Program 3 - Drug Profile
Product Description
Mechanism Of Action
TYK2 (JH2) Program 4 - Drug Profile
Product Description
Mechanism Of Action
VTX-958 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Dormant Products
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Discontinued Products
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Nov 08, 2022: Sareum Holdings : Update on SDC-1801 CTA application
Sep 28, 2022: Alumis announces initiation of patient dosing in phase 2 clinical trial of ESK-001 for the treatment of plaque psoriasis
Sep 12, 2022: Bristol Myers Squibb announces new Sotyktu (deucravacitinib) long-term data showing clinical efficacy maintained for up to two years with continuous treatment in moderate-to-severe plaque psoriasis
Sep 09, 2022: US FDA grants approval for BMS’ Sotyktu to treat plaque psoriasis
Aug 24, 2022: Nimbus Therapeutics presents new data on oral allosteric TYK2 inhibitor at American Chemical Society Meeting
Aug 15, 2022: Ventyx Biosciences announces positive topline phase 1 data for its selective allosteric TYK2 inhibitor VTX95
Aug 11, 2022: Ventyx Biosciences to report topline results from the phase 1 trial of its TYK 2 inhibitor VTX958 and second quarter 2022 financial results on August 15, 2022
Aug 02, 2022: InnoCare announces first subject dosed in clinical trial of TYK2 JH2 allosteric inhibitor ICP-488 in China
Jul 28, 2022: Sareum submits clinical trial authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an operational update
Jun 28, 2022: Roivant and Pfizer unveil Priovant Therapeutics and ongoing registrational studies for oral Brepocitinib in dermatomyositis and lupus
Jun 01, 2022: Late-Breaking data at EULAR 2022 demonstrate deucravacitinib significantly improved disease activity in phase 2 PAISLEY study in Systemic Lupus Erythematosus
Jun 01, 2022: Lupus Research Alliance and Lupus Therapeutics response to positive data from phase 2 study on potential first-in-class lupus treatment
May 19, 2022: Nimbus Therapeutics presents additional clinical data from phase 1 studies of oral allosteric TYK2 inhibitor at SID Annual Meeting
May 12, 2022: New two-year deucravacitinib data reinforce durable efficacy and consistent safety profile in treatment of moderate to severe plaque psoriasis
Apr 11, 2022: European patent granted for Sareum's SDC-1802, a novel small molecule TYK2/JAK1 inhibitor, for the treatment of T-cell acute lymphoblastic leukaemia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Indications, 2022 (Contd..2)
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by A2A Pharmaceuticals Inc, 2022
Pipeline by Alexion Pharmaceuticals Inc, 2022
Pipeline by Alumis Inc, 2022
Pipeline by Amgen Inc, 2022
Pipeline by Atomwise Inc, 2022
Pipeline by BeiGene Ltd, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by Galapagos NV, 2022
Pipeline by Haisco Pharmaceutical Group Co Ltd, 2022
Pipeline by InnoCare Pharma Ltd, 2022
Pipeline by Kinaset Therapeutics Inc, 2022
Pipeline by Merck & Co Inc, 2022
Pipeline by Neuron23 Inc, 2022
Pipeline by Nimbus Therapeutics LLC, 2022
Pipeline by Oncostellae SL, 2022
Pipeline by Pfizer Inc, 2022
Pipeline by Priovant Therapeutics Inc, 2022
Pipeline by Sareum Holdings Plc, 2022
Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
Pipeline by Simcere Pharmaceutical Group Ltd, 2022
Pipeline by Sudo Biosciences Inc, 2022
Pipeline by Technoderma Medicines Inc, 2022
Pipeline by Theravance Biopharma Inc, 2022
Pipeline by TLL Pharmaceutical LLC, 2022
Pipeline by Ventyx Biosciences Inc, 2022
Pipeline by Xilingyuan Pharmaceutical Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Discontinued Products, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Indications, 2022 (Contd..2)
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by A2A Pharmaceuticals Inc, 2022
Pipeline by Alexion Pharmaceuticals Inc, 2022
Pipeline by Alumis Inc, 2022
Pipeline by Amgen Inc, 2022
Pipeline by Atomwise Inc, 2022
Pipeline by BeiGene Ltd, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by Galapagos NV, 2022
Pipeline by Haisco Pharmaceutical Group Co Ltd, 2022
Pipeline by InnoCare Pharma Ltd, 2022
Pipeline by Kinaset Therapeutics Inc, 2022
Pipeline by Merck & Co Inc, 2022
Pipeline by Neuron23 Inc, 2022
Pipeline by Nimbus Therapeutics LLC, 2022
Pipeline by Oncostellae SL, 2022
Pipeline by Pfizer Inc, 2022
Pipeline by Priovant Therapeutics Inc, 2022
Pipeline by Sareum Holdings Plc, 2022
Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
Pipeline by Simcere Pharmaceutical Group Ltd, 2022
Pipeline by Sudo Biosciences Inc, 2022
Pipeline by Technoderma Medicines Inc, 2022
Pipeline by Theravance Biopharma Inc, 2022
Pipeline by TLL Pharmaceutical LLC, 2022
Pipeline by Ventyx Biosciences Inc, 2022
Pipeline by Xilingyuan Pharmaceutical Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Discontinued Products, 2022
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
